Psychiatr. pro Praxi, 2010; 11(4): 143-144

A new advancements in the biological therapy of dementias

doc.MUDr.Roman Jirák, CSc.
Psychiatrická klinika 1. LF UK a VFN Praha

The basic survey of some biological methods of dementia therapy, first of all Alzheimer´s disease clinically tested in present time is

described in this article.

Keywords: Alzheimer disease, beta- and gamma-secretase inhibitors, dementia, phosphodiesterase inhibitors, stem cells, vaccines

Published: December 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirák R. A new advancements in the biological therapy of dementias. Psychiatr. praxi. 2010;11(4):143-144.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ghosh AK, Kumaragurubaran N, Hong L, et al. Memapsin 2 (beta-secretase) inhibitors: drug development. Curr Alzheimer Res. 2008; 5(2): 121-113. Go to original source... Go to PubMed...
    2. Zhu Yi-ping, Xiao K, Yu Hai-ping, et al. Discovery of potent beta-secretase (bace-1) inhibitors by the synthesi of isophtalamide-containing hybrids. Acta Pharmacologica Sinica, 2009; 30: 259-269. Go to original source... Go to PubMed...
    3. Grosveld GC. Gamma-secretase inhibitors: Notch sob ad. Nature Medicine, 2009; 15: 20-21. Go to original source... Go to PubMed...
    4. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patiens with mild Alzheimer disease. JAMA 2009; 302(23): 2557-2564. Go to original source... Go to PubMed...
    5. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta imunotherapy? Nat Rev Neurol. 2010; 6(2): 108-119. Go to original source... Go to PubMed...
    6. Zilka N, Konstekova E, Novak M. Chaperone-like antibodies targeting misfolded tau protein: New vista in the immunotherapy of neurodegenerative foldopathies. Journal of Alzheimer´s Disease, 2008; 15(2): 169-179. Go to original source... Go to PubMed...
    7. Ghavami A, Hirst WD, Novak TJ. Selective (PDE)-4 inhibitors: A novel approach to treating memory deficit? Drugs in R&D, 2006; 7(2): 63-71. Go to original source... Go to PubMed...
    8. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory and anuloid-B load in an Alzheimer´s disease mouse model. The Journal of Neuroscience 2009; 29(25): 8075-8086. Go to original source... Go to PubMed...
    9. Rose GM, Hopper A, De Vivo M, Tehim A. Phosphodiesterase inhibitors for cognitive enhancement. Current Pharmaceutical Design 2005; 11(26): 3329-3334. Go to original source... Go to PubMed...
    10. Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nature Biotechnology 2010; 28: 63-70. Go to original source... Go to PubMed...
    11. Buckingham SD, Jines AK, Brown LA, et al. Nicotinic acetylcholine receptor sigmalling: Roles in Alzheimer´s disease and anuloid neuroprotectiom. Pharmacol. Rev., 2009; 61(1): 39-61. Go to original source... Go to PubMed...
    12. Hernandez CM, Kayed R, Zheng H, et al. Loss of alfa7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal patology in a mouse model of Alzheimer´s disease. The Journal of Neuroscience 2010; 30(7): 2442-2453. Go to original source... Go to PubMed...
    13. Ikonomovic MD, Wecker L, Abrahamson EE, et al. Cortical alfa7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch neurol. 2009; 66(5): 646-651. Go to original source... Go to PubMed...
    14. Liu Q, Juany Y, Xue F, et al. A novel nicotinis acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to anuloid peptides. The Journal of Neuroscience 2009; 29(4): 918-929. Go to original source... Go to PubMed...
    15. Colloby SJ, Pakrasi S, Perry AK, et al. The effects of donepezil on nicotinic receptor status in dementia: a 123I-5IA-85380 SPECT study. J Neurol Neurosurg Psychiatry 2008; 79: 485-487. Go to original source...
    16. Obšil T, Pavlíček Z. Glykace proteinů a fosfolipidů: Maillardova reakce in vivo. Chem. Listy 1997; 91: 558-569.
    17. Racci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). The FASEB Journal, Publisher online before print July 4, 2008 as doi: 10.1096/fj.08-109033. Go to original source... Go to PubMed...
    18. Clynes R, Moser B, Yan SF, et al. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med. 2007; 7(8): 743-751. Go to original source... Go to PubMed...
    19. Desai K, Wu L. Methylglyoxal and advanced glycation endproducts: bew therapeutic horizons? Recent Patents Cardiovasc Drug Discov. 2007; 2(2): 89-99. Go to original source... Go to PubMed...
    20. Mrak RE and Landreth GE: PPARgama, neuroinflammation, and disease. Journal of Neuroinflammation 2004, 1:5 doi: 10.1186/1742-2094-1-5. Go to original source... Go to PubMed...
    21. Griffin WST. Perispinal etanercept: Potential as an Alzheimer therapeutic. Journal of Neuroinflammation 2008; 5: 3 doi: 10.1186/1742-2094-5-3. Go to original source... Go to PubMed...
    22. Bolanos JP, Moro MA, Lizasoain I, et al. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications. Advanced Drug Delivery Reviews 2009; 61: 1299-1315. Go to original source... Go to PubMed...
    23. Bonda DJ, Wang X, Gustaw-Rothenberg KA, et al. Mitochondrial drugs for Alzheimer disease. Pharmaceuticals 2009; 2(3): 287-298. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.